Hadassah

Placental Cells Mitigate Radiation-Induced Complications in Mice, Hadassah Researchers Reveal

Wednesday, Jun 26 2013

Placental cells, Hadassah Medical Organization researchers have shown, were successful in mitigating acute radiation-induced complications in mice when transplantation was initiated 24 hours following total body irradiation.

The research team from Hadassah's Biotechnology and Radiobiology Laboratory at the Sharett Institute of Oncology studied two types of placental cells--pure maternal cell preparations (PLX-Mat) and a mixture of maternal ¬and fetal derived cells (PLX-RAD), developed by Pluristem Therapeutics, a leading developer of placenta-based cell therapies. Using intramuscular (IM) injections, they were able to overcome the difficulty experienced by other researchers whereby, with intravenous treatment, the stem cells became trapped mostly in the lungs immediately after administration. Rather, IM injections enabled them to easily deliver higher numbers of cells through multiple injections at different times.

Twenty four hours and five days after total body irradiation, the mice were treated with placental stromal cells (PLX). The researchers discovered that PLX-Mat increased the survival of the irradiation mice from 27 percent to 68 percent, while PLX-RAD cells increased the survival to 98 percent. The researchers found that they could delay the treatment with PLX-RAD up to 48 hours after irradiation with similar success. The study showed that the treated mice regained their weight significantly faster than did the few control survivors. Furthermore, the treatment stimulated extensive hematopoietic (blood producing) stem cell proliferation, which enabled the speedy recovery of the radiation-induced depleted bone marrow with a parallel increase in the number of circulating white blood cells, red blood cells, and platelets.

The authors conclude: "Our study suggests that IM treatment with PLX-RAD cells may serve as a highly effective 'off the shelf' therapy to treat bone marrow failure following total body exposure to high doses of radiation." These cells can be stored, delivered frozen, and then defrosted just before injection.

The researchers add that they expect the treatment may also have major applications for clinical conditions associated with severe bone marrow aplasia, where blood cell development is impaired.

Read more here>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 23 2016

2016 Graduates from 19 Countries Celebrate Hadassah’s IMPH Program

Singing "It's a Wonderful Country" in Hebrew, wearing their native dress, the members of the 41st International Master of Public Health (IMPH) program of the Hadassah-Hebrew University Braun School of Public Health and Community Medicine celebrated their graduation.

READ MORE ›
alt_text

Monday, Sep 19 2016

Hadassah Hospital Treats Terror Victims After Stabbing Attacks

This last week has brought a burst of terror attacks.

READ MORE ›
alt_text

Thursday, Sep 15 2016

“Stunning Results” Continue with Hadassah’s Stem Cell Treatment to Reverse MS

The Hadassah Medical Center is continuing to receive positive findings with its Phase II clinical trial using its unique stem cell approach to stop the progression and reversing the disabilities of multiple sclerosis.

READ MORE ›
alt_text

Thursday, Sep 15 2016

2012 Hadassah Stage-Four Melanoma Patient Thankfully Healthy

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said Hadassah melanoma patient Stewart Greenberg.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More